The Life Raft Group invites you to “Exploring The SARC044 Trial: Key Details & What The GIST Community Can Gain From The Study” on January 8th, 2024 at 2:30PM ET. Dr. Candace Haddox, Dana-Farber Cancer Institute, will present an overview of the Phase II SARC044 Clinical Trial. This currently recruiting study tests the investigational use of bezuclastinib in combination with sunitinib in patients with GIST. Webinar participants will learn about the SARC044 study, including eligibility, site locations, and study rationale. A Q&A session will follow the presentation.

About Our Presenter

Dr. Candace Haddox
Dana-Farber Cancer Institute

Dr. Candace Haddox is an Instructor in Medicine at Harvard Medical School, and a medical oncologist and clinical/translational investigator in the Sarcoma Center and the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute. Dr. Haddox’s research focuses on developing novel therapies rooted in sarcoma biology and determining mechanisms of treatment response and resistance, particularly in gastrointestinal stromal tumors (GIST).

Dr. Haddox received her Bachelor of Science in neurobiology from the University of Miami. She completed a post-baccalaureate research fellowship at the National Institutes of Health and received her Medical Degree from the University of South Florida. Dr. Haddox completed a residency in Internal Medicine at the Mayo Clinic in Rochester, Minnesota, and a fellowship in Medical Oncology at Duke University, where she also served as Chief Fellow. She joined the faculty at Dana-Farber Cancer Institute in 2021, where she currently sees patients with sarcomas and leads clinical trials in early drug development.